View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Jan. 27 (HealthDay News) -- Bydureon (exenatide extended release), Amylin Pharmaceuticals' long-acting version of the diabetes drug Byetta, has been approved by the U.S. Food and Drug Administration.
The once-weekly injection will include a label warning that the drug caused certain thyroid tumors in rats, the Dow Jones news service reported. It's not known whether the drug causes such tumors in people, the label warning says. But the drug shouldn't be used by people with a family history of medullary thyroid carcinoma, the warning continues.
Twice in 2010, the FDA declined approval of Bydureon, requesting additional studies and clinical information, Dow Jones reported.
Bydureon is a glucagon-like peptide-1 receptor, a class of medications that helps the body produce more insulin, which helps regulate blood sugar.
Amylin is based in San Diego, Calif.
For more about type 2 diabetes, visit MedlinePlus.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top